Morgan Stanley Starts C4 Therapeutics (CCCC) at Underweight
Tweet
Share
E-mailGet Alerts CCCC Hot Sheet
Price: $4.24 +3.92%
Rating Summary:
10 Buy, 5 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
10 Buy, 5 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Morgan Stanley analyst Terence Flynn initiates coverage on C4 Therapeutics (NASDAQ: CCCC) with a Underweight rating and a price target of $6.00.
For an analyst ratings summary and ratings history on C4 Therapeutics click here. For more ratings news on C4 Therapeutics click here.
Shares of C4 Therapeutics closed at $7.73 yesterday.
You May Also Be Interested In
- C4 Therapeutics, Inc. (CCCC) Tops Q2 EPS by 3c
- Jefferies Starts Aehr Test Systems (AEHR) at Buy
- UBS Starts Schrodinger (SDGR) at Neutral
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
